بدائل البحث:
significantly improve » significantly improved (توسيع البحث)
improve decrease » improve disease (توسيع البحث), improved urease (توسيع البحث), improves disease (توسيع البحث)
greater decrease » greatest decrease (توسيع البحث), greater increase (توسيع البحث), greater disease (توسيع البحث)
we decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), nn decrease (توسيع البحث)
significantly improve » significantly improved (توسيع البحث)
improve decrease » improve disease (توسيع البحث), improved urease (توسيع البحث), improves disease (توسيع البحث)
greater decrease » greatest decrease (توسيع البحث), greater increase (توسيع البحث), greater disease (توسيع البحث)
we decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), nn decrease (توسيع البحث)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
Supplementary file 1_Intercropping of short- and tall-stature maize decreases lodging risk without yield penalty at high planting density.docx
منشور في 2025"…Compared with IND, IHD did not significantly improve the population yield. The upper leaf area of intercropped XY was greater than sole stand, leading to increased interception of photosynthetically active radiation (PAR). …"
-
8
-
9
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
-
10
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
-
11
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20